CANCER THERAPY: PRECLINICAL

1442 Patient-Derived First Generation Xenografts of Non–Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy
Xin Dong, Jun Guan, John C. English, Julia Flint, John Yee, Kenneth Evans, Nevin Murray, Calum MacAulay, Raymond T. Ng, Peter W. Gout, Wan L. Lam, Janessa Laskin, Victor Ling, Stephen Lam, and Yuzhuo Wang

1452 Comparative Profiling of the Novel Epothilone, Sagopilone, in Xenografts Derived from Primary Non–Small Cell Lung Cancer
Stefanie Hammer, Anette Sommer, Iduna Fichtner, Michael Becker, Jana Rolff, Johannes Merk, Ulrich Klar, and Jens Hoffmann

1466 An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicity and Enhanced Therapeutic Efficacy without Oncogenicity
Zachary Hartman, Junping Wei, Takuya Osada, Oliver Glass, Gangjun Lei, Xiao-Yi Yang, Sharon Peplinski, Dong-Wan Kim, Wenle Xia, Neil Spector, Jeffrey Marks, William Barry, Amy Hobeika, Gayathri Devi, Andrea Amalfitano, Michael A. Morse, H. Kim Lyerly, and Timothy M. Clay

1478 Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma
Radhika Iyer, Audrey E. Evans, Xiaoxue Qi, Ruth Ho, Jane E. Minturn, Huaqing Zhao, Naomi Balamuth, John M. Maris, and Garrett M. Brodeur

1486 Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer with Acquired Endocrine Resistance

1498 Preclinical Investigation of PEGylated Tumor Necrosis Factor α in Dogs with Spontaneous Tumors: Phase 1 Evaluation
Douglas H. Thamm, Ilene D. Kurzman, Mike A. Clark, E.J. Ehrhart III, Susan L. Kraft, Daniel L. Gustafson, and David M. Vail

IMAGING, DIAGNOSIS, PROGNOSIS

1509 Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo
Zev A. Wainberg, Adrian Anghel, Amrita J. Desai, Raul Ayala, Tong Luo, Brent Safra, Marlena S. Fejzo, J. Randolph Hecht, Dennis J. Slamon, and Richard S. Finn

1520 Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma
Toshihiko Ishii, Takashi Ishida, Atae Utsunomiya, Atsushi Inagaki, Hiroki Yano, Hirokazu Komatsu, Shinsuke lida, Kazunori Imada, Takashi Uchiyama, Shiro Akinaga, Kenya Shitara, and Ryuzo Ueda

1532 Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature
Katleen De Preter, Joëlle Vermeulen, Benedikt Brors, Olivier Delattre, Angelika Egert, Matthias Fischer, Isabelle Janoueix-Lerosey, Cinzia Lavarino, John M. Maris, Jaune Mora, Akira Nakagawa, André Obertuer, Miki Ohira, Gudrun Schleiermacher, Alexander Schramm, Johannes H. Schulte, Qun Wang, Frank Westermann, Frank Speleman, and Jo Vandeseompele

1542 Evaluation of Treatment-Associated Inflammatory Response on Diffusion-Weighted Magnetic Resonance Imaging and 2-[18F]-Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography Imaging Biomarkers

1553 Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer
A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry

Evaluation of the ETS-Related Gene mRNA in Urine for the Detection of Prostate Cancer

Melanoma MicroRNA Signature Predicts Post-Recurrence Survival

Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab
Howard M. Stern, Mary Padilla, Klaus Wagner, Lukas Amler, and Avi Ashkenazi

IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendrogial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
Martin J. van den Bent, Hendrikus J. Dubbink, Yannick Marie, Alba A. Brandes, Martin J.B. Taphoorn, Pieter Wesseling, Marc Frenay, Coe C. Tijssen, Denis Lacombe, Ahmed Idbaih, Ronald van Marion, Johan M. Kros, Winand N.M. Dijstems, Thierry Gorlia, and Marc Sanson

Cyclooxygenase-2 Inhibition Does Not Improve the Reduction in Ductal Carcinoma In situ Proliferation with Aromatase Inhibitor Therapy: Results of the ERISAC Randomized Placebo-Controlled Trial

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
Josefine Becker, Lambert Skoog, Tommy Fomander, Bo Nordenskjöld, and Olle Stål

A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma
Hui Huang, Michael Menefee, Maureen Edgerly, Sen Zhuang, Herb Kotz, Marianne Poruchynsky, Lyn Mickley Huff, Susan Bates, and Tito Fojo

Diverse Patterns of T-Cell Response against Multiple Newly Identified Human Y Chromosome–Encoded Minor Histocompatibility Epitopes
Yishai Ofran, Haesook T. Kim, Vladimir Brusic, Loren Blake, Michael Mandrell, Catherine J. Wu, Stefanie Sarantopoulos, Roberto Bellucci, Derin B. Keskin, Robert J. Soiffer, Joseph H. Antin, and Jerome Ritz
Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma

Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma

Phase 1 Experience with an Anti-Glycopote Monoclonal Antibody, RAV12, in Recurrent Adenocarcinoma

Implications of LINE1 Methylation for Bladder Cancer Risk in Women

Corrections: PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients

Correction: MicroRNA Expression in Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus: Associations with Survival

LETTERS TO THE EDITOR

Is High-Grade Prostate Cancer Easier to Find in Smaller Prostates Because There Is More High-Grade Disease to Find? - Letter

Is High-Grade Prostate Cancer Easier to Find in Smaller Prostates Because There Is More High-Grade Disease to Find? - Response

SUSCEPTIBILITY AND PREVENTION

Implications of LINE1 Methylation for Bladder Cancer Risk in Women

ABOUT THE COVER

The featured image is a lung adenocarcinoma stained with a novel, highly sensitive and specific antibody recognizing the ALK oncoprotein (brown staining) and counterstained with hematoxylin (blue staining). The tumor was shown to harbor a rearrangement of the ALK locus by genetic analysis. This assay will facilitate the routine identification of ALK-rearranged lung adenocarcinomas in clinical practice and detect lung cancers that may be responsive to ALK inhibitors. For details, see the article by Mino-Kenudson and colleagues on page 1561 of this issue.